Cannabis Science Inc (OTCMKTS:CBIS) is a play we had been relatively bearish on just about all year up until late October, when we felt the technical extent of the bear market for this stock may have completed its course for the time being. Since then, we’ve tried to start focusing on what’s positive in this story. In that vein, one place to start is certainly the company’s most recent announcement: namely, that, very soon, CBIS will release its newest version of the Patient Access Center (PAC), an exclusive online community for social networking and information sharing platform.

According to the release, “by bringing together Doctors, Patients, Industry Professionals, Lawyers, Scientists, Civil and Constitutional Rights Activists, Legalization Efforts Groups and many others, we are building a powerful knowledge center of real-world data of successful treatment stories, formal clinical study information, to mobilizing large groups for upcoming events, or certain demographics that need help to help effective change for each area of concern or question.”

Cannabis Science Inc (OTCMKTS:CBIS) is a company that has been actively striving for, and achieving a bump in legitimacy through some of its newly established relationships. However, the concept of sales still seems far off, which is a bit remarkable.

CBIS defines itself according to the narrative of a leading-edge researcher and designer of cannabinoid solutions to health problems.

CBIS is involved in developing medicines for autism, blood pressure, cancer and cancer side effects, as well as for other illnesses comprising for general health maintenance. It also develops CS-TATI-1 for newly diagnosed and treatment-experienced patients with drug-resistant HIV strains, as well as those intolerant of available therapies; CS-S/BCC-1 to treat basal and squamous cell carcinomas; and a proprietary cannabis-based therapy for neurological conditions.

In addition, CBIS offers an online video-based medical cannabis education system, including courses, such as medical cannabis law, medical marijuana, cooking, horticulture, and bud tending; and manufactures and distributes specialty horse and pet grooming and topical applications. It has a license agreement with Apothecary Genetics Investments LLC to produce various brand formulations for California medical cannabis market.

Find out when $CBIS reaches critical levels. Subscribe to Right Now by entering your Email in the box below.

As discussed above, CBIS has taken a tough road so far in 2017, but may be starting to do some interesting things. As a case in point, the company just announced that it is just about to release its newest version of the Patient Access Center, which represents a platform for exclusive online community social networking and information sharing.

According to the release, “through 24/7 real-time communications and interaction between its members, this platform will create an information exchange game changer, pushing forward the movement of Cannabis and Hemp education, drug development, and to help fix the ineffective patient treatment and access because of the illegal conflicts of interest between the individual State Governments vs the Federal Government for Cannabis and Hemp cultivation, drug development and distribution laws. Thus making safe access for patients in need confusing, unattainable, and extremely frustrating for people who have seen, believe, and genuinely want to learn about the miraculous healing powers of the plant.”

Recent action has seen 4% tacked on to share pricing for the name in the past week, but that move comes in the context of a larger bearish trend. Market participants may want to pay attention to this stock. CBIS has a history of dramatic rallies. In addition, the stock has witnessed a pop in interest, as transaction volume levels have recently pushed 10% beyond its prior sustained average level.

At this time, carrying a capital value in the market of $92.8M, CBIS has a chunk ($322K) of cash on the books, which compares with about $2.3M in total current liabilities. One should also note that debt has been growing over recent quarters. CBIS is pulling in very nominal trailing 12-month revenues (just $7K). However, the company is seeing declines on the top-line on a quarterly y/y basis, with revenues falling at -91.2%. We will update the story again soon as further details emerge. Sign-up for continuing coverage on shares of $CBIS stock, as well as other hot stock picks, get our free newsletter today and get our next breakout pick!

Disclosure: we hold no position in $CBIS, either long or short, and we have not been compensated for this article.